NCT06492005

A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer

A Phase II Clinical Study of Efficacy and Safety of 9MW2821Monotherapy or Combined With PD-1 Inhibitor in Locally Advanced or Metastatic Triple-Negative Breast Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a Phase 2, open-label,multicenter study designed to evaluate the efficacy and safety of 9MW2821monotherapy or combined with PD-1 inhibitor in locally advanced or metastatic Triple-Negative Breast Cancer.

Conditions

• Triple-Negative Breast Cancer

Interventions

Type	Name	Description
DRUG	9MW2821	Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol
DRUG	PD-1 inhibitior	Subjects will receive intravenous (IV) infusion of PD-1 inhibitor as per protocol

Timeline

• Start date: 2024-07-26
• Primary completion: 2026-07-01
• Completion: 2027-07-01
• First posted: 2024-07-09
• Last updated: 2025-01-10

Locations

1 site across 1 country: China